← 產業報告目錄

Autoimmunity Diagnostics Market by Product (Consumables, Instruments), Test Type (Routine, Autoantibody, Inflammatory, Urinalysis Tests), Disease (RA, SLE, MS, IBD), End User (Clinical Laboratories, Hospitals & Clinics) - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-08-07頁數 299報告編號 MD5936

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The autoimmune disease diagnosis market is projected to reach USD 8.98 billion by 2031 from USD 5.57 billion in 2025, at a CAGR of 8.3% during the forecast period. This growth is driven by the rising prevalence of autoimmune disorders, increasing awareness of early diagnosis, and technological advancements such as multiplex immunoassays and biomarker-based tests. Additionally, the growing adoption of automated platforms and supportive government initiatives contribute to increased testing volumes and improved diagnostic accuracy. By disease type, the systemic autoimmune diseases segment accounted for the largest market share in 2024. Based on disease type, the global autoimmune disease diagnosis market is segmented into systemic autoimmune diseases and organ-specific autoimmune diseases. The systemic autoimmune diseases segment accounted for the largest market share in 2024. The large share of this region is attributed to the widespread prevalence of conditions such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. These diseases typically affect multiple organs and systems, necessitating frequent and comprehensive diagnostic evaluations. The complexity of diagnosis, reliance on advanced immunological tests, and the need for continuous disease monitoring drive higher demand for diagnostic solutions in this segment. By end user, the clinical laboratories segment accounted for the largest market share during the forecast period. Based on end users, the autoimmune disease diagnosis market is segmented into clinical laboratories, hospitals & clinics, and other end users. Among these, the clinical laboratories segment accounted for the largest market share owing to specialized expertise, advanced diagnostic technologies, and high-throughput capabilities. Equipped with automated platforms such as ELISA, chemiluminescence, and immunofluorescence, these laboratories can perform complex tests with high accuracy and efficiency. Their role as centralized testing hubs allows them to process large sample volumes at reduced per-test costs. Asia Pacific: The fastest-growing region in the autoimmune disease diagnosis market during the forecast period. The autoimmune disease diagnosis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the region is primarily driven by the rising prevalence of autoimmune diseases, increasing healthcare expenditure, the growing adoption of advanced diagnostic technologies, and heightened awareness about early disease detection across emerging economies. Additionally, improvements in healthcare infrastructure and supportive government initiatives further contribute to market expansion in the Asia Pacific region. The break-up of the profile of primary participants in the autoimmune disease diagnosis market: • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30% • By Designation: C-level - 27%, D-level - 18%, and Others - 55% • By Region: North America - 51%, Europe - 21%, the Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa- 4% The key players in the market are Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Grifols S.A. (Spain), Werfen S.A. (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Exagen Inc. (US), Trinity Biotech plc (Ireland), Tecan Group Ltd. (Switzerland), Danaher Corporation (US), BIOSYNEX SA (France), QuidelOrtho Corporation (US), Revvity, Inc. (US), bioMérieux SA (France), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), SD Biosensor, INC. (Korea), Cambridge Life Sciences Ltd (UK), A. Menarini Diagnostics s.r.l (Italy), Sebia (France), KRONUS (US), Erba Group (Czech Republic), AESKU.GROUP GmbH (Germany), Medsource Ozone Biomedicals Pvt. Ltd. (India), and Epitope Diagnostics Inc. (US). Research Coverage: This research report categorizes the autoimmune disease diagnosis market by product (consumables and instruments), by test type (routine laboratory tests, inflammatory tests, autoantibodies and immunologic tests, urinalysis tests, and other tests), by disease type (systemic autoimmune diseases and organ-specific autoimmune diseases), by end user (clinical laboratories, hospitals & clinics, and other end users), and by region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report's scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the autoimmune disease diagnosis market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the autoimmune disease diagnosis market. This report covers the competitive analysis of upcoming startups in the autoimmune disease diagnosis market ecosystem. Reasons to buy this report: The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall autoimmune disease diagnosis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (High incidence of autoimmune diseases, rising awareness related to early disease diagnosis, growing number of r&d activities for innovative diagnostic solutions, advancements in diagnostic technologies), restraints (high capital requirements), opportunities (utilization of biosensors for autoimmune disease diagnosis, growth potential of emerging economies, growing number of reagent rental agreements), and challenges (complexities associated with diagnosis of autoimmune diseases, shortage of skilled professionals) influencing the growth of the autoimmune disease diagnosis market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the autoimmune disease diagnosis market. • Market Development: Comprehensive information about lucrative markets – the report analyses the autoimmune disease diagnosis market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoimmune disease diagnosis market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Revvity, Inc. (US), Thermo Fisher Scientific Inc. (US), and Siemens Healthineers AG (Germany).
目錄 Table of Contents
1 INTRODUCTION 28 1.1 STUDY OBJECTIVES 28 1.2 MARKET DEFINITION 28 1.3 STUDY SCOPE 29 1.3.1 MARKETS COVERED & REGIONAL SCOPE 29 1.3.2 INCLUSIONS & EXCLUSIONS 30 1.3.3 YEARS CONSIDERED 31 1.3.4 CURRENCY CONSIDERED 31 1.4 KEY STAKEHOLDERS 31 1.5 SUMMARY OF CHANGES 32 2 RESEARCH METHODOLOGY 33 2.1 RESEARCH DATA 33 2.1.1 SECONDARY DATA 34 2.1.1.1 Key secondary sources 34 2.1.1.2 Key data from secondary sources 35 2.1.2 PRIMARY RESEARCH 36 2.1.2.1 Key primary sources 36 2.1.2.2 Key data from primary sources 37 2.1.2.3 Key industry insights 38 2.2 MARKET SIZE ESTIMATION 39 2.2.1 BOTTOM-UP APPROACH 39 2.2.1.1 Approach 1: Company revenue estimation approach 40 2.2.1.2 Approach 2: Presentations of companies and primary interviews 40 2.2.1.3 Growth forecast 41 2.2.1.4 CAGR projections 41 2.2.2 TOP-DOWN APPROACH 41 2.3 MARKET BREAKDOWN & DATA TRIANGULATION 43 2.4 MARKET SHARE ASSESSMENT 43 2.5 RESEARCH ASSUMPTIONS 44 2.5.1 PARAMETRIC ASSUMPTIONS 44 2.6 RESEARCH LIMITATIONS 44 2.7 RISK ASSESSMENT 45 3 EXECUTIVE SUMMARY 46   4 PREMIUM INSIGHTS 50 4.1 AUTOIMMUNITY DIAGNOSTICS MARKET OVERVIEW 50 4.2 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2031 51 4.3 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2031 51 4.4 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2031 52 4.5 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2031 52 4.6 AUTOIMMUNITY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53 5 MARKET OVERVIEW 54 5.1 INTRODUCTION 54 5.2 MARKET DYNAMICS 54 5.2.1 DRIVERS 55 5.2.1.1 High incidence of autoimmune diseases 55 5.2.1.2 Rising awareness related to early disease diagnosis 56 5.2.1.3 Increasing number of R&D activities for innovative diagnostic solutions 56 5.2.1.4 Advancements in diagnostic technologies 57 5.2.2 RESTRAINTS 58 5.2.2.1 High capital requirements 58 5.2.3 OPPORTUNITIES 59 5.2.3.1 Utilization of biosensors for autoimmune disease diagnosis 59 5.2.3.2 Growth potential of emerging economies 59 5.2.3.3 Growing number of reagent rental agreements 60 5.2.4 CHALLENGES 60 5.2.4.1 Complexities associated with diagnosis of autoimmune diseases 60 5.2.4.2 Shortage of skilled professionals 60 5.3 PRICING ANALYSIS 61 5.3.1 INDICATIVE SELLING PRICE TREND, BY PRODUCT, 2023−2025 61 5.3.2 INDICATIVE SELLING PRICE TREND OF ASSAYS, BY KEY PLAYER, 2023−2025 61 5.3.3 INDICATIVE SELLING PRICE TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, BY REGION, 2023−2025 62 5.4 PATENT ANALYSIS 63 5.4.1 LIST OF MAJOR PATENTS 64 5.5 VALUE CHAIN ANALYSIS 64 5.6 SUPPLY CHAIN ANALYSIS 66 5.7 TRADE ANALYSIS 67 5.7.1 IMPORT DATA (HS CODE 3822) 67 5.7.2 EXPORT DATA (HS CODE 3822) 68 5.8 ECOSYSTEM ANALYSIS 68 5.8.1 ROLE IN ECOSYSTEM 69   5.9 PORTER’S FIVE FORCES ANALYSIS 69 5.9.1 THREAT OF NEW ENTRANTS 71 5.9.2 THREAT OF SUBSTITUTES 71 5.9.3 BARGAINING POWER OF BUYERS 71 5.9.4 BARGAINING POWER OF SUPPLIERS 71 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 71 5.10 KEY STAKEHOLDERS & BUYING CRITERIA 71 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 72 5.10.2 BUYING CRITERIA 73 5.10.3 REGULATORY LANDSCAPE 73 5.10.3.1 North America 73 5.10.3.1.1 US 73 5.10.3.1.2 Canada 74 5.10.3.2 Europe 74 5.10.3.2.1 Germany 75 5.10.3.2.2 UK 75 5.10.3.2.3 France 75 5.10.3.2.4 Italy 75 5.10.3.3 Asia Pacific 76 5.10.3.3.1 China 76 5.10.3.3.2 Japan 76 5.10.3.3.3 India 76 5.10.3.3.4 Australia 77 5.10.3.4 Latin America 77 5.10.3.5 Middle East 77 5.10.3.5.1 Africa 78 5.10.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 5.11 TECHNOLOGY ANALYSIS 80 5.11.1 KEY TECHNOLOGIES 80 5.11.1.1 Immunoassays 80 5.11.2 COMPLEMENTARY TECHNOLOGIES 81 5.11.2.1 Flow cytometry 81 5.12 KEY CONFERENCES & EVENTS, 2025–2026 82 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83 5.14 INVESTMENT & FUNDING SCENARIO 84 5.15 CASE STUDY ANALYSIS 84 5.15.1 CASE STUDY 1: LABORATORY-BASED DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS 84 5.15.2 CASE STUDY 2: DIAGNOSTIC IMPORTANCE OF AUTOANTIBODY TESTING IN IDENTIFICATION OF LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA) 85   5.16 IMPACT OF AI/GENERATIVE AI ON AUTOIMMUNITY DIAGNOSTICS MARKET 85 5.16.1 INTRODUCTION 85 5.16.2 MARKET POTENTIAL OF AI 86 5.16.3 AI USE CASES 86 5.16.4 IMPLEMENTATION OF AI, BY KEY COMPANY AND CASE 87 5.16.5 FUTURE OF AI IN AUTOIMMUNITY DIAGNOSTICS MARKET 87 5.17 TRUMP TARIFF IMPACT ON AUTOIMMUNITY DIAGNOSTICS MARKET 87 5.17.1 INTRODUCTION 87 5.17.2 KEY TARIFF RATES 88 5.17.3 PRICE IMPACT ANALYSIS 89 5.17.4 KEY IMPACT ON COUNTRY/REGION 89 5.17.4.1 North America 89 5.17.4.2 Europe 89 5.17.4.3 Asia Pacific 89 5.17.5 IMPACT ON END-USE INDUSTRIES 89 5.17.5.1 Clinical laboratories 90 5.17.5.2 Hospitals & clinics 90 6 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT 91 6.1 INTRODUCTION 92 6.2 CONSUMABLES 92 6.2.1 RECURRING PURCHASE FOR HIGH VOLUME OF DIAGNOSTIC TESTING TO PROPEL MARKET 92 6.3 INSTRUMENTS 95 6.3.1 GROWING NEED FOR AUTOMATION AND HIGH-THROUGHPUT TESTING TO DRIVE MARKET 95 7 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE 98 7.1 INTRODUCTION 99 7.2 AUTOANTIBODIES AND IMMUNOLOGIC TESTS 99 7.2.1 ACCURATE DETECTION & MONITORING ABILITIES FOR BROAD APPLICATIONS TO PROPEL MARKET 99 7.3 ROUTINE LABORATORY TESTS 102 7.3.1 RECURRENT TESTING DUE TO COST EFFICIENCY TO BOOST DEMAND 102 7.4 INFLAMMATORY TESTS 104 7.4.1 ABILITY OF INFLAMMATORY MARKERS TO DETECT ABNORMALITIES TO DRIVE MARKET 104 7.5 URINALYSIS TESTS 106 7.5.1 TECHNOLOGICAL ADVANCEMENTS IN URINE ANALYZERS TO FUEL UPTAKE 106 7.6 OTHER TESTS 108   8 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE 110 8.1 INTRODUCTION 111 8.2 SYSTEMIC AUTOIMMUNE DISEASES 111 8.2.1 RHEUMATOID ARTHRITIS 114 8.2.1.1 Uptake of rheumatoid factor immunological test to boost demand 114 8.2.2 SYSTEMIC LUPUS ERYTHEMATOSUS 116 8.2.2.1 Utilization of autoimmune testing kits for constant monitoring to propel market 116 8.2.3 PSORIASIS 119 8.2.3.1 Frequent association with systemic inflammation and comorbidities to boost demand 119 8.2.4 MULTIPLE SCLEROSIS 121 8.2.4.1 Public-private investments for MS awareness to fuel market 121 8.2.5 OTHER SYSTEMIC AUTOIMMUNE DISEASES 123 8.3 ORGAN-SPECIFIC AUTOIMMUNE DISEASES 125 8.3.1 TYPE-1 DIABETES 128 8.3.1.1 Rising global incidence among children & adults to fuel market 128 8.3.2 CELIAC DISEASE 131 8.3.2.1 Growing awareness regarding gluten sensitivity and improved testing availability to drive market 131 8.3.3 INFLAMMATORY BOWEL DISEASE 133 8.3.3.1 Growing awareness of chronic gastrointestinal autoimmune disorders to fuel market 133 8.3.4 OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASES 135 9 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER 138 9.1 INTRODUCTION 139 9.2 CLINICAL LABORATORIES 139 9.2.1 ABILITY TO CONDUCT HIGH VOLUME OF SPECIALIZED TESTS TO PROPEL MARKET 139 9.3 HOSPITALS & CLINICS 141 9.3.1 GROWING AWARENESS OF EARLY DISEASE DIAGNOSIS TO FUEL UPTAKE 141 9.4 OTHER END USERS 144 10 AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION 146 10.1 INTRODUCTION 147 10.2 NORTH AMERICA 147 10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 148 10.2.2 US 152 10.2.2.1 High healthcare expenditure and expansive research initiatives for product commercialization to boost demand 152 10.2.3 CANADA 156 10.2.3.1 Rising prevalence of chronic autoimmune conditions to drive market 156   10.3 EUROPE 159 10.3.1 EUROPE: MACROECONOMIC OUTLOOK 160 10.3.2 UK 163 10.3.2.1 Growing R&D efforts for early disease diagnosis to fuel uptake 163 10.3.3 GERMANY 166 10.3.3.1 Increasing incidence of multiple sclerosis to drive market 166 10.3.4 FRANCE 169 10.3.4.1 Expansion of lab modernization to support market growth 169 10.3.5 ITALY 172 10.3.5.1 Growing disease burden and aging demographics to fuel market 172 10.3.6 SPAIN 175 10.3.6.1 Prevalence of celiac disease to drive market 175 10.3.7 REST OF EUROPE 178 10.4 ASIA PACIFIC 181 10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 181 10.4.2 CHINA 187 10.4.2.1 Government initiatives for early autoimmune disease screening to fuel market 187 10.4.3 JAPAN 190 10.4.3.1 Rapidly aging population and advanced healthcare infrastructure to boost demand 190 10.4.4 INDIA 193 10.4.4.1 Government-led healthcare initiatives and rapid expansion of diagnostic infrastructure to propel market 193 10.4.5 AUSTRALIA 196 10.4.5.1 Increasing incidences of autoimmune diseases to support market growth 196 10.4.6 REST OF ASIA PACIFIC 199 10.5 LATIN AMERICA 202 10.5.1 INCREASING INCIDENCE OF TYPE-1 DIABETES TO FUEL MARKET 202 10.5.2 LATIN AMERICA: MACROECONOMIC OUTLOOK 203 10.6 MIDDLE EAST & AFRICA 206 10.6.1 FAVORABLE GOVERNMENT INITIATIVES FOR EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET GROWTH 206 10.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 207 11 COMPETITIVE LANDSCAPE 211 11.1 INTRODUCTION 211 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 211 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET 211 11.3 REVENUE ANALYSIS, 2022−2024 213 11.4 MARKET SHARE ANALYSIS, 2024 214 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 216 11.5.1 STARS 216 11.5.2 EMERGING LEADERS 216 11.5.3 PERVASIVE PLAYERS 216 11.5.4 PARTICIPANTS 216 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 218 11.5.5.1 Company footprint 218 11.5.5.2 Region footprint 218 11.5.5.3 Product footprint 219 11.5.5.4 Test type footprint 219 11.5.5.5 Disease type footprint 220 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 220 11.6.1 PROGRESSIVE COMPANIES 220 11.6.2 RESPONSIVE COMPANIES 221 11.6.3 DYNAMIC COMPANIES 221 11.6.4 STARTING BLOCKS 221 11.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 222 11.6.5.1 Detailed list of key startups/SMEs 222 11.6.5.2 Competitive benchmarking of startups/SMEs 222 11.7 COMPANY VALUATION & FINANCIAL METRICS 223 11.7.1 FINANCIAL METRICS 223 11.7.2 COMPANY VALUATION 224 11.8 BRAND/PRODUCT COMPARISON 224 11.9 COMPETITIVE SCENARIO 225 11.9.1 PRODUCT LAUNCHES & APPROVALS 225 11.9.2 DEALS 225 11.9.3 EXPANSIONS 226 11.9.4 OTHER DEVELOPMENTS 226 12 COMPANY PROFILES 227 12.1 KEY PLAYERS 227 12.1.1 F. HOFFMANN-LA ROCHE LTD. 227 12.1.1.1 Business overview 227 12.1.1.2 Products offered 228 12.1.1.3 MnM view 229 12.1.1.3.1 Key strengths 229 12.1.1.3.2 Strategic choices 229 12.1.1.3.3 Weaknesses & competitive threats 229 12.1.2 ABBOTT LABORATORIES 230 12.1.2.1 Business overview 230 12.1.2.2 Products offered 231 12.1.2.3 MnM view 232 12.1.2.3.1 Key strengths 232 12.1.2.3.2 Strategic choices 232 12.1.2.3.3 Weaknesses & competitive threats 232 12.1.3 REVVITY, INC. 233 12.1.3.1 Business overview 233 12.1.3.2 Products offered 234 12.1.3.3 Recent developments 236 12.1.3.3.1 Product launches 236 12.1.3.4 MnM view 237 12.1.3.4.1 Key strengths 237 12.1.3.4.2 Strategic choices 237 12.1.3.4.3 Weaknesses & competitive threats 237 12.1.4 THERMO FISHER SCIENTIFIC INC. 238 12.1.4.1 Business overview 238 12.1.4.2 Products offered 239 12.1.4.3 Recent developments 240 12.1.4.3.1 Product launches 240 12.1.4.3.2 Deals 241 12.1.4.3.3 Other developments 241 12.1.4.4 MnM view 241 12.1.4.4.1 Key strengths 241 12.1.4.4.2 Strategic choices 242 12.1.4.4.3 Weaknesses & competitive threats 242 12.1.5 SIEMENS HEALTHINEERS AG 243 12.1.5.1 Business overview 243 12.1.5.2 Products offered 244 12.1.5.3 Recent developments 245 12.1.5.3.1 Product approvals 245 12.1.5.3.2 Deals 246 12.1.5.4 MnM view 246 12.1.5.4.1 Key strengths 246 12.1.5.4.2 Strategic choices 246 12.1.5.4.3 Weaknesses & competitive threats 247 12.1.6 BIO-RAD LABORATORIES, INC. 248 12.1.6.1 Business overview 248 12.1.6.2 Products offered 249 12.1.7 GRIFOLS S.A. 251 12.1.7.1 Business overview 251 12.1.7.2 Products offered 252 12.1.7.3 Recent developments 253 12.1.7.3.1 Deals 253   12.1.8 WERFEN S.A. 254 12.1.8.1 Business overview 254 12.1.8.2 Products offered 255 12.1.8.3 Recent developments 257 12.1.8.3.1 Product approvals 257 12.1.9 EXAGEN INC. 258 12.1.9.1 Business overview 258 12.1.9.2 Products offered 259 12.1.9.3 Recent developments 260 12.1.9.3.1 Product launches 260 12.1.9.3.2 Deals 260 12.1.10 TRINITY BIOTECH PLC 261 12.1.10.1 Business overview 261 12.1.10.2 Products offered 263 12.1.11 TECAN GROUP LTD. 264 12.1.11.1 Business overview 264 12.1.11.2 Products offered 265 12.1.12 DANAHER CORPORATION 267 12.1.12.1 Business overview 267 12.1.12.2 Products offered 269 12.1.12.3 Recent developments 269 12.1.12.3.1 Deals 269 12.1.13 BIOSYNEX SA 270 12.1.13.1 Business overview 270 12.1.13.2 Products offered 271 12.1.13.3 Recent developments 272 12.1.13.3.1 Deals 272 12.1.14 QUIDELORTHO CORPORATION 273 12.1.14.1 Business overview 273 12.1.14.2 Products offered 274 12.1.14.3 Recent developments 275 12.1.14.3.1 Expansions 275 12.1.15 BIOMÉRIEUX SA 276 12.1.15.1 Business overview 276 12.1.15.2 Products offered 277 12.1.16 DIASORIN S.P.A. 278 12.1.16.1 Business overview 278 12.1.16.2 Products offered 280 12.1.16.3 Recent developments 280 12.1.16.3.1 Deals 280   12.2 OTHER PLAYERS 281 12.2.1 BECTON, DICKINSON AND COMPANY 281 12.2.2 SD BIOSENSOR, INC. 282 12.2.3 CAMBRIDGE LIFE SCIENCES LTD 283 12.2.4 A. MENARINI DIAGNOSTICS S.R.L 284 12.2.5 SEBIA 285 12.2.6 KRONUS 286 12.2.7 ERBA GROUP 287 12.2.8 AESKU.GROUP GMBH 288 12.2.9 MEDSOURCE OZONE BIOMEDICALS PVT. LTD. 289 12.2.10 EPITOPE DIAGNOSTICS INC. 290 13 APPENDIX 291 13.1 DISCUSSION GUIDE 291 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 295 13.3 CUSTOMIZATION OPTIONS 297 13.4 RELATED REPORTS 297 13.5 AUTHOR DETAILS 298
圖表清單 List of Tables & Figures
TABLE 1 AUTOIMMUNITY DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES 37 TABLE 2 AUTOIMMUNITY DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 45 TABLE 3 NIH-FUNDED INVESTMENTS & GRANTS, BY DISEASE TYPE 57 TABLE 4 A FEW RECENT EXAMPLES OF INNOVATIONS IN AUTOIMMUNE DIAGNOSTIC TECHNOLOGIES ARE LISTED BELOW: 58 TABLE 5 INDICATIVE SELLING PRICING TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, 2023–2025 61 TABLE 6 INDICATIVE SELLING PRICE TREND OF ASSAYS, BY KEY PLAYER, 2023–2025 61 TABLE 7 INDICATIVE SELLING PRICE TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, BY REGION, 2023–2025 62 TABLE 8 AUTOIMMUNITY DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS, 2023–2024 64 TABLE 9 IMPORT DATA (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 67 TABLE 10 EXPORT DATA (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 68 TABLE 11 AUTOIMMUNITY DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 69 TABLE 12 AUTOIMMUNITY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 70 TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS (%) 72 TABLE 14 KEY BUYING CRITERIA FOR AUTOIMMUNITY DIAGNOSTICS PRODUCTS 73 TABLE 15 CLASSIFICATION OF IVD DEVICES IN EUROPE 74 TABLE 16 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 76 TABLE 17 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 18 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 19 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 20 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 21 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 22 AUTOIMMUNITY DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 82 TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES 88 TABLE 24 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 92 TABLE 25 KEY COMPANIES OFFERING CONSUMABLES 93 TABLE 26 AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2023–2031 (USD MILLION) 93 TABLE 27 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 94 TABLE 28 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 94 TABLE 29 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 94 TABLE 30 KEY COMPANIES OFFERING INSTRUMENTS 96 TABLE 31 AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023–2031 (USD MILLION) 96 TABLE 32 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2031 (USD MILLION) 96 TABLE 33 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2031 (USD MILLION) 97 TABLE 34 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2031 (USD MILLION) 97 TABLE 35 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 99 TABLE 36 AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY REGION, 2023–2031 (USD MILLION) 101 TABLE 37 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 101 TABLE 38 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 101 TABLE 39 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 102 TABLE 40 AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY REGION, 2023–2031 (USD MILLION) 103 TABLE 41 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 103 TABLE 42 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 103 TABLE 43 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 104 TABLE 44 AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY REGION, 2023–2031 (USD MILLION) 105 TABLE 45 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 105 TABLE 46 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 105 TABLE 47 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 106 TABLE 48 AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS, BY REGION, 2023–2031 (USD MILLION) 107 TABLE 49 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 107 TABLE 50 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 107 TABLE 51 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 108 TABLE 52 AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS, BY REGION, 2023–2031 (USD MILLION) 108 TABLE 53 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 109 TABLE 54 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 109 TABLE 55 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 109 TABLE 56 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 111 TABLE 57 SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 112 TABLE 58 SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION, 2023–2031 (USD MILLION) 112 TABLE 59 NORTH AMERICA: SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 113 TABLE 60 EUROPE: SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 113 TABLE 61 ASIA PACIFIC: SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 113 TABLE 62 KEY COMPANIES CURRENTLY OFFERING RHEUMATOID ARTHRITIS PRODUCTS 115 TABLE 63 AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2023–2031 (USD MILLION) 115 TABLE 64 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023–2031 (USD MILLION) 115 TABLE 65 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023–2031 (USD MILLION) 116 TABLE 66 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023–2031 (USD MILLION) 116 TABLE 67 KEY COMPANIES CURRENTLY OFFERING SYSTEMIC LUPUS ERYTHEMATOSUS PRODUCTS 117 TABLE 68 AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2023–2031 (USD MILLION) 117 TABLE 69 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2023–2031 (USD MILLION) 118 TABLE 70 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2023–2031 (USD MILLION) 118 TABLE 71 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2023–2031 (USD MILLION) 118 TABLE 72 AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS, BY REGION, 2023–2031 (USD MILLION) 119 TABLE 73 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS, BY COUNTRY, 2023–2031 (USD MILLION) 120 TABLE 74 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS, BY COUNTRY, 2023–2031 (USD MILLION) 120 TABLE 75 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS, BY COUNTRY, 2023–2031 (USD MILLION) 120 TABLE 76 KEY COMPANIES CURRENTLY OFFERING MULTIPLE SCLEROSIS PRODUCTS 121 TABLE 77 AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2023–2031 (USD MILLION) 122 TABLE 78 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023–2031 (USD MILLION) 122 TABLE 79 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023–2031 (USD MILLION) 122 TABLE 80 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023–2031 (USD MILLION) 123 TABLE 81 KEY COMPANIES CURRENTLY OFFERING OTHER SYSTEMIC AUTOIMMUNE DISEASE PRODUCTS 124 TABLE 82 OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY REGION, 2023–2031 (USD MILLION) 124 TABLE 83 NORTH AMERICA: OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 124 TABLE 84 EUROPE: OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 125 TABLE 85 ASIA PACIFIC: OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 125 TABLE 86 ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY TYPE, 2023–2031 (USD MILLION) 126 TABLE 87 ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION, 2023–2031 (USD MILLION) 127 TABLE 88 NORTH AMERICA: ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 127 TABLE 89 EUROPE: ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 127 TABLE 90 ASIA PACIFIC: ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128 TABLE 91 NUMBER OF PEOPLE LIVING WITH TYPE 1 DIABETES, 2024 129 TABLE 92 KEY COMPANIES CURRENTLY OFFERING TYPE 1 DIABETES PRODUCTS 129 TABLE 93 AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE 1 DIABETES, BY REGION, 2023–2031 (USD MILLION) 129 TABLE 94 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE 1 DIABETES, BY COUNTRY, 2023–2031 (USD MILLION) 130 TABLE 95 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE 1 DIABETES, BY COUNTRY, 2023–2031 (USD MILLION) 130 TABLE 96 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE 1 DIABETES, BY COUNTRY, 2023–2031 (USD MILLION) 130 TABLE 97 KEY COMPANIES OFFERING CELIAC DISEASE PRODUCTS 131 TABLE 98 AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE, BY REGION, 2023–2031 (USD MILLION) 132 TABLE 99 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE, BY COUNTRY, 2023–2031 (USD MILLION) 132 TABLE 100 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE, BY COUNTRY, 2023–2031 (USD MILLION) 132 TABLE 101 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE, BY COUNTRY, 2023–2031 (USD MILLION) 133 TABLE 102 KEY COMPANIES OFFERING INFLAMMATORY BOWEL DISEASE PRODUCTS 133 TABLE 103 AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2023–2031 (USD MILLION) 134 TABLE 104 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2023–2031 (USD MILLION) 134 TABLE 105 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2023–2031 (USD MILLION) 134 TABLE 106 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2023–2031 (USD MILLION) 135 TABLE 107 KEY COMPANIES CURRENTLY OFFERING OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASE PRODUCTS 136 TABLE 108 OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY REGION, 2023–2031 (USD MILLION) 136 TABLE 109 NORTH AMERICA: OTHER ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 136 TABLE 110 EUROPE: OTHER ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 137 TABLE 111 ASIA PACIFIC: OTHER ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 137 TABLE 112 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 139 TABLE 113 AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2023–2031 (USD MILLION) 140 TABLE 114 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 140 TABLE 115 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 141 TABLE 116 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 141 TABLE 117 NUMBER OF HOSPITALS, BY COUNTRY, 2023 142 TABLE 118 AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2031 (USD MILLION) 142 TABLE 119 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 143 TABLE 120 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 143 TABLE 121 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 143 TABLE 122 AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION) 144 TABLE 123 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 144 TABLE 124 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 145 TABLE 125 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 145 TABLE 126 AUTOIMMUNITY DIAGNOSTICS MARET, BY REGION, 2023–2031 (USD MILLION) 147 TABLE 127 NORTH AMERICA: MACROECONOMIC INDICATORS 148 TABLE 128 NORTH AMERICA: NUMBER OF RHEUMATOID ARTHRITIS (RA) CASES, BY COUNTRY, 2023–2031 149 TABLE 129 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 150 TABLE 130 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 150 TABLE 131 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 150 TABLE 132 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 151 TABLE 133 NORTH AMERICA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 151 TABLE 134 NORTH AMERICA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 152 TABLE 135 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 152 TABLE 136 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 153 TABLE 137 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 154 TABLE 138 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 154 TABLE 139 US: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 155 TABLE 140 US: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 155 TABLE 141 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 155 TABLE 142 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 156 TABLE 143 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 157 TABLE 144 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 157 TABLE 145 CANADA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 158 TABLE 146 CANADA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 158 TABLE 147 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 159 TABLE 148 EUROPE: MACROECONOMIC INDICATORS 160 TABLE 149 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 160 TABLE 150 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 161 TABLE 151 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 161 TABLE 152 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 161 TABLE 153 EUROPE: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 162 TABLE 154 EUROPE: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 162 TABLE 155 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 163 TABLE 156 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 164 TABLE 157 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 164 TABLE 158 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 164 TABLE 159 UK: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 165 TABLE 160 UK: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 165 TABLE 161 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 165 TABLE 162 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 166 TABLE 163 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 167 TABLE 164 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 167 TABLE 165 GERMANY: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 168 TABLE 166 GERMANY: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 168 TABLE 167 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 169 TABLE 168 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 170 TABLE 169 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 170 TABLE 170 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 170 TABLE 171 FRANCE: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 171 TABLE 172 FRANCE: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 171 TABLE 173 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 172 TABLE 174 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 173 TABLE 175 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 173 TABLE 176 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 173 TABLE 177 ITALY: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 174 TABLE 178 ITALY: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 174 TABLE 179 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 174 TABLE 180 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 175 TABLE 181 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 176 TABLE 182 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 176 TABLE 183 SPAIN: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 177 TABLE 184 SPAIN: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 177 TABLE 185 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 178 TABLE 186 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 179 TABLE 187 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 179 TABLE 188 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 179 TABLE 189 REST OF EUROPE: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 180 TABLE 190 REST OF EUROPE: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 180 TABLE 191 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 181 TABLE 192 ASIA PACIFIC: MACROECONOMIC INDICATORS 182 TABLE 193 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 184 TABLE 194 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 184 TABLE 195 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 185 TABLE 196 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 185 TABLE 197 ASIA PACIFIC: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 186 TABLE 198 ASIA PACIFIC: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 186 TABLE 199 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 187 TABLE 200 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 188 TABLE 201 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 188 TABLE 202 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 188 TABLE 203 CHINA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 189 TABLE 204 CHINA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 189 TABLE 205 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 190 TABLE 206 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 191 TABLE 207 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 191 TABLE 208 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 191 TABLE 209 JAPAN: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 192 TABLE 210 JAPAN: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 192 TABLE 211 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 193 TABLE 212 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 194 TABLE 213 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 194 TABLE 214 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 195 TABLE 215 INDIA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 195 TABLE 216 INDIA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 196 TABLE 217 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 196 TABLE 218 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 197 TABLE 219 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 197 TABLE 220 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 198 TABLE 221 AUSTRALIA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 198 TABLE 222 AUSTRALIA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 199 TABLE 223 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 199 TABLE 224 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 200 TABLE 225 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 200 TABLE 226 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 201 TABLE 227 REST OF ASIA PACIFIC: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 201 TABLE 228 REST OF ASIA PACIFIC: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 202 TABLE 229 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 202 TABLE 230 LATIN AMERICA: MACROECONOMIC INDICATORS 203 TABLE 231 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 204 TABLE 232 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 204 TABLE 233 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 204 TABLE 234 LATIN AMERICA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 205 TABLE 235 LATIN AMERICA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 205 TABLE 236 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 206 TABLE 237 MIDDLE EAST & AFRICA: MACROINDICATORS 207 TABLE 238 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 207 TABLE 239 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 208 TABLE 240 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 208 TABLE 241 MIDDLE EAST & AFRICA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 209 TABLE 242 MIDDLE EAST & AFRICA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 209 TABLE 243 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 210 TABLE 244 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET, JANUARY 2021–MAY 2025 211 TABLE 245 AUTOIMMUNITY DIAGNOSTICS MARKET: DEGREE OF COMPETITION 214 TABLE 246 AUTOIMMUNITY DIAGNOSTICS MARKET: REGION FOOTPRINT 218 TABLE 247 AUTOIMMUNITY DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 219 TABLE 248 AUTOIMMUNITY DIAGNOSTICS MARKET: TEST TYPE FOOTPRINT 219 TABLE 249 AUTOIMMUNITY DIAGNOSTICS MARKET: DISEASE TYPE FOOTPRINT 220 TABLE 250 AUTOIMMUNITY DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 222 TABLE 251 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY PRODUCT AND DISEASE TYPE 222 TABLE 252 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY REGION 223 TABLE 253 AUTOIMMUNITY DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 225 TABLE 254 AUTOIMMUNITY DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MAY 2025 225 TABLE 255 AUTOIMMUNITY DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–MAY 2025 226 TABLE 256 AUTOIMMUNITY DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2025 226 TABLE 257 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 227 TABLE 258 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 228 TABLE 259 ABBOTT LABORATORIES: COMPANY OVERVIEW 230 TABLE 260 ABBOTT LABORATORIES: PRODUCTS OFFERED 231 TABLE 261 REVVITY, INC.: COMPANY OVERVIEW 233 TABLE 262 REVVITY, INC.: PRODUCTS OFFERED 234 TABLE 263 REVVITY, INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025 236 TABLE 264 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 238 TABLE 265 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 239 TABLE 266 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025 240 TABLE 267 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MAY 2025 241 TABLE 268 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS, JANUARY 2021−MAY 2025 241 TABLE 269 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 243 TABLE 270 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 244 TABLE 271 SIEMENS HEALTHINEERS AG: PRODUCT APPROVALS, JANUARY 2021– MAY 2025 245 TABLE 272 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021– MAY 2025 246 TABLE 273 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 248 TABLE 274 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 249 TABLE 275 GRIFOLS S.A.: COMPANY OVERVIEW 251 TABLE 276 GRIFOLS S.A.: PRODUCTS OFFERED 252 TABLE 277 GRIFOLS S.A.: DEALS, JANUARY 2021– MAY 2025 253 TABLE 278 WERFEN S.A.: COMPANY OVERVIEW 254 TABLE 279 WERFEN S.A.: PRODUCTS OFFERED 255 TABLE 280 WERFEN S.A.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 257 TABLE 281 EXAGEN INC.: COMPANY OVERVIEW 258 TABLE 282 EXAGEN INC.: PRODUCTS OFFERED 259 TABLE 283 EXAGEN INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025 260 TABLE 284 EXAGEN INC.: DEALS, JANUARY 2021–MAY 2025 260 TABLE 285 TRINITY BIOTECH PLC: COMPANY OVERVIEW 261 TABLE 286 TRINITY BIOTECH PLC: PRODUCTS OFFERED 263 TABLE 287 TECAN GROUP LTD.: COMPANY OVERVIEW 264 TABLE 288 TECAN GROUP LTD.: PRODUCTS OFFERED 265 TABLE 289 DANAHER CORPORATION: COMPANY OVERVIEW 267 TABLE 290 DANAHER CORPORATION: PRODUCTS OFFERED 269 TABLE 291 DANAHER CORPORATION: DEALS, JANUARY 2021– MAY 2025 269 TABLE 292 BIOSYNEX SA: COMPANY OVERVIEW 270 TABLE 293 BIOSYNEX SA: PRODUCTS OFFERED 271 TABLE 294 BIOSYNEX SA: DEALS, JANUARY 2021– MAY 2025 272 TABLE 295 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 273 TABLE 296 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 274 TABLE 297 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021– MAY 2025 275 TABLE 298 BIOMÉRIEUX SA: COMPANY OVERVIEW 276 TABLE 299 BIOMÉRIEUX SA: PRODUCTS OFFERED 277 TABLE 300 DIASORIN S.P.A.: COMPANY OVERVIEW 278 TABLE 301 DIASORIN S.P.A.: PRODUCTS OFFERED 280 TABLE 302 DIASORIN S.P.A.: DEALS, JANUARY 2021– MAY 2025 280 TABLE 303 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 281 TABLE 304 SD BIOSENSOR, INC.: COMPANY OVERVIEW 282 TABLE 305 CAMBRIDGE LIFE SCIENCES LTD.: COMPANY OVERVIEW 283 TABLE 306 A. MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW 284 TABLE 307 SEBIA: COMPANY OVERVIEW 285 TABLE 308 KRONUS: COMPANY OVERVIEW 286 TABLE 309 ERBA GROUP: COMPANY OVERVIEW 287 TABLE 310 AESKU.GROUP GMBH: COMPANY OVERVIEW 288 TABLE 311 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.: COMPANY OVERVIEW 289 TABLE 312 EPITOPE DIAGNOSTICS INC.: COMPANY OVERVIEW 290 FIGURE 1 MARKET SEGMENTATION & REGIONAL SCOPE 29 FIGURE 2 AUTOIMMUNITY DIAGNOSTICS MARKET: RESEARCH DESIGN 33 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 38 FIGURE 4 BREAKDOWN OF PRIMARIES 39 FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 40 FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41 FIGURE 7 AUTOIMMUNITY DIAGNOSTICS MARKET: TOP-DOWN APPROACH 42 FIGURE 8 DATA TRIANGULATION METHODOLOGY 43 FIGURE 9 AUTOIMMUNITY DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS 44 FIGURE 10 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2031 (USD MILLION) 46 FIGURE 11 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2031 (USD MILLION) 47 FIGURE 12 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2031 (USD MILLION) 47 FIGURE 13 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2031 (USD MILLION) 48 FIGURE 14 AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2031 (USD MILLION) 49 FIGURE 15 RISING PREVALENCE OF AUTOIMMUNE DISEASES AND INCREASING ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES TO PROPEL MARKET 50 FIGURE 16 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 51 FIGURE 17 AUTOANTIBODIES AND IMMUNOLOGIC TESTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 51 FIGURE 18 SYSTEMIC AUTOIMMUNE DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 52 FIGURE 19 CLINICAL LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 52 FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 53 FIGURE 21 AUTOIMMUNITY DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54 FIGURE 22 PATENT ANALYSIS FOR IMMUNOASSAYS (JANUARY 2014–DECEMBER 2024) 63 FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING ASSEMBLY PHASES 65 FIGURE 24 AUTOIMMUNITY DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 66 FIGURE 25 AUTOIMMUNITY DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 69 FIGURE 26 AUTOIMMUNITY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 70 FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR AUTOIMMUNITY DIAGNOSTICS PRODUCTS 72 FIGURE 28 KEY BUYING CRITERIA FOR AUTOIMMUNITY DIAGNOSTICS PRODUCTS 73 FIGURE 29 AUTOIMMUNITY DIAGNOSTICS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83 FIGURE 30 NUMBER OF DEALS & FUNDING ACTIVITIES IN AUTOIMMUNITY DIAGNOSTICS MARKET 84 FIGURE 31 MARKET POTENTIAL OF AI IN AUTOIMMUNITY DIAGNOSTICS MARKET 86 FIGURE 32 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS SNAPSHOT 149 FIGURE 33 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS SNAPSHOT 183 FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET (2022–2024) 213 FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET (2024) 214 FIGURE 36 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 217 FIGURE 37 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPANY FOOTPRINT 218 FIGURE 38 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 221 FIGURE 39 EV/EBITDA OF KEY VENDORS 223 FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 224 FIGURE 41 AUTOIMMUNITY DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS 224 FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 228 FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2024) 231 FIGURE 44 REVVITY, INC.: COMPANY SNAPSHOT (2024) 234 FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 239 FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 244 FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 249 FIGURE 48 GRIFOLS S.A.: COMPANY SNAPSHOT (2024) 252 FIGURE 49 WERFEN S.A: COMPANY SNAPSHOT (2024) 255 FIGURE 50 EXAGEN INC.: COMPANY SNAPSHOT (2024) 258 FIGURE 51 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2023) 262 FIGURE 52 TECAN GROUP LTD.: COMPANY SNAPSHOT (2024) 265 FIGURE 53 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 268 FIGURE 54 BIOSYNEX SA: COMPANY SNAPSHOT (2024) 270 FIGURE 55 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024) 274 FIGURE 56 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2024) 277 FIGURE 57 DIASORIN S.P.A.: COMPANY SNAPSHOT (2024) 279

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們